Testing GRPR PET Scan for Prostate Cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new imaging method (GRPR PET) to help better see and stage prostate cancer. If you have prostate cancer, this scan may give doctors more detail about where the cancer is located.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer, whether you have been treated before or not.
- You are willing to sign a consent form agreeing to take part in the study.
- You do not have a known allergy to PSMA (the imaging agent used in this study).
- You do not have any medical condition that would keep you from following the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of imaging scans (a PSMA PET scan and an MRI) to see which is better at finding prostate cancer. You may be able to join if you are scheduled for prostate removal surgery and haven't started cancer treatment yet.
This trial tests whether a special PET/MRI scan (using a tracer called 68Ga-PSMA-11) can better identify the main tumor in men with early prostate cancer who are planning surgery. The goal is to help doctors target treatment more precisely in the future.
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
This study tests whether a special scan (PSMA PET/MRI) combined with a standard MRI can better detect prostate cancer. It is for men who have not had a biopsy yet and are suspected of having prostate cancer.
This trial tests a new PET scan called XACP3 to see if it can find prostate cancer as well as the standard PSMA PET scan. You could help by having both scans to compare them.
This study tests a new PET/CT imaging agent that targets a protein called GRPR, which is found on many cancer cells. The goal is to see if this scan can help detect or evaluate various cancers, which might improve diagnosis and treatment planning.
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.